In re Application of:

Roddi J. SIMPSON et al.

Serial No. 10/657,171

Art Unit: 3763

Filed: September 9, 2003

Examiner: Han, Mark K.

For: FIXED NEEDLE SYRINGE

WITH PROTECTIVE

HOUSING

Atty Docket: 0100/0162

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT FILED PURSUANT TO 37 CFR 1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

For insuring compliance with the applicants' duty of disclosure under 37 CFR §1.56, the undersigned hereby submits the attached Form PTO-1449 listing a reference for consideration by the Examiner in charge of the above-identified patent application.

The attached Terumo publication is not believed to be prior art to the instant invention inasmuch as it was published after the filing date of the instant application.

These documents are being submitted:

within three months of the filing of the above U.S. national application or of the date of entry of the U.S. national stage in an International Patent Application (no fee is due); (37 CFR §1.97(b))

[XX] before receiving a first Office Action on the merits of the aboveidentified patent application (no fee is due); (37 CFR §1.97(b))

following receipt of a first Office Action, but before issuance of a Final Office Action or a Notice of Allowance (if this box is checked, one of the last three boxes also must be checked); (37 CFR  $\S1.97(c)$ concurrently with the filing of the RCE (37 CFR 1.114) OR following receipt of a Notice of Allowance or a Final Office Action. The undersigned hereby requests consideration of this Information Disclosure Statement after the mailing the Final Office Action or Notice of Allowance by filing this Information Disclosure Statement under 37 CFR §1.97(d) The Commissioner is authorized to debit \$180.00 for payment of the fee set forth in 37 CFR § 1.17(p). (37 CFR §1.97(d)(2)) The undersigned certifies that each item of this information is being submitted within three months of the date it was cited European Patent Office in a counterpart application. (37 CFR §1.97(e)(1)) The undersigned certifies that, after making reasonable inquiry, П he/she has no knowledge that any item of this information was cited by a foreign patent office in a counterpart application or was known

The Commissioner is hereby authorized to charge payment of any deficiency in the above fee(s) or to charge any additional fees required under 37 CFR § 1.16 or 1.17 or credit any overpayment to Deposit Account No. 50-0501. A duplicate copy of this authorization is attached for the Finance Branch.

more than three months prior to this submission. (37 CFR

Respectfully submitted,

Louis Woo, Reg. No. 31,730 Law Offices of Louis Woo

717 North Fayette Street Alexandria, Virginia 22314

Phone: (703) 299-4090

Date: May 23, 2005

§1.97(e)(2))

**FORM PTO-1449** 

MAY 2 3 2005 G

Atty	Docket 0100/0162
	0100/0162

Serial No.

10/657,171

Applicant

INFORMATION DISCLOSURE CITATION

Roddi James Simpson et al.

Filing Date September 9, 2003 Group Art Unit 3763

			U.S. PATE	NT DOCUMENTS			
Examiner Initial		Document Number	Date	Name	Class	Sub- Class	Filing Date
	AA		•				
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						<del></del>
	AJ						
	AK						
		FC	DREIGN PA	TENT DOCUMENTS			
		Document Number	Date	Country	Class	Sub- Class	Trans- lation
	AL						
	AM						
	AN						
	AO						
	AP						
		OTHER (Include	ding Author,	Title, Date, Pertinent Pa	ges, etc.)		
	AR	Terumo Sur Jan. 2005	Guard Safet	y Insulin Syringe, Terum	o Medical (	Corporati	on,
	AS						
	АТ						
Examiner		<u> </u>		Date Consider	ed		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.